Literature DB >> 10075952

Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole.

D Gillen1, A A Wirz, W D Neithercut, J E Ardill, K E McColl.   

Abstract

BACKGROUND: Omeprazole has a greater intragastric pH elevating effect in Helicobacter pylori positive than negative subjects. Ammonia production by H pylori has been suggested as a probable mechanism. AIMS: To assess the effect of H pylori status on gastric acid secretion during omeprazole treatment, and to examine the possible role of ammonia neutralisation of intragastric acid in increased omeprazole efficacy in infected subjects.
METHODS: Twenty H pylori positive and 12 H pylori negative healthy volunteers were examined before and six to eight weeks after commencing omeprazole 40 mg/day. On both occasions plasma gastrin and acid output were measured basally and in response to increasing doses of gastrin 17 (G-17). Gastric juice ammonium concentrations were also measured.
RESULTS: Prior to omeprazole, measurements were similar in the H pylori positive and negative subjects. During omeprazole, median basal intragastric pH was higher in the H pylori positive (7.95) versus negative (3.75) subjects (p<0.002). During omeprazole basal, submaximal (180 pmol/kg/h G-17), and maximal acid outputs (800 pmol/kg/h G-17) were lower in H pylori positive subjects (0.0, 3.6, 6.0 mmol/h respectively) versus negative subjects (0.3, 14.2, 18.6 mmol/h) (p<0.03 for each). This effect was not explained by neutralisation by ammonia.
CONCLUSION: The presence of H pylori infection leads to a more profound suppression of acid secretion during omeprazole treatment. The effect cannot be explained by neutralisation of intragastric acid by bacterial ammonia production and its precise mechanism has to be explained.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10075952      PMCID: PMC1727447          DOI: 10.1136/gut.44.4.468

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  57 in total

1.  Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia.

Authors:  R Eissele; G Brunner; B Simon; E Solcia; R Arnold
Journal:  Gastroenterology       Date:  1997-03       Impact factor: 22.682

2.  The British Society of Gastroenterology spring meeting 20-22 March 1996. Abstracts.

Authors: 
Journal:  Gut       Date:  1996       Impact factor: 23.059

3.  Effect of age on the frequency of active Campylobacter pylori infection diagnosed by the [13C]urea breath test in normal subjects and patients with peptic ulcer disease.

Authors:  D Y Graham; P D Klein; A R Opekun; T W Boutton
Journal:  J Infect Dis       Date:  1988-04       Impact factor: 5.226

4.  Severe diarrehoea due to small intestinal colonisation during cimetidine treatment.

Authors:  W S Ruddell; M S Losowsky
Journal:  Br Med J       Date:  1980-07-26

5.  Improved fold width and increased acid secretion after eradication of the organism in Helicobacter pylori associated enlarged fold gastritis.

Authors:  Y Yasunaga; Y Shinomura; S Kanayama; M Yabu; T Nakanishi; Y Miyazaki; Y Murayama; J J Bonilla-Palacios; Y Matsuzawa
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

6.  Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole.

Authors:  E F Verdú; D Armstrong; J P Idström; J Labenz; M Stolte; G Dorta; G Börsch; A L Blum
Journal:  Gut       Date:  1995-12       Impact factor: 23.059

7.  Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer.

Authors:  J Labenz; B Tillenburg; U Peitz; J P Idström; E F Verdú; M Stolte; G Börsch; A L Blum
Journal:  Gastroenterology       Date:  1996-03       Impact factor: 22.682

8.  Interleukin-1 is cytoprotective, antisecretory, stimulates PGE2 synthesis by the stomach, and retards gastric emptying.

Authors:  A Robert; A S Olafsson; C Lancaster; W R Zhang
Journal:  Life Sci       Date:  1991       Impact factor: 5.037

9.  Interaction of Helicobacter pylori and its fatty acids with parietal cells and gastric H+/K(+)-ATPase.

Authors:  W Beil; C Birkholz; S Wagner; K F Sewing
Journal:  Gut       Date:  1994-09       Impact factor: 23.059

10.  A comparison of five maintenance therapies for reflux esophagitis.

Authors:  S Vigneri; R Termini; G Leandro; S Badalamenti; M Pantalena; V Savarino; F Di Mario; G Battaglia; G S Mela; A Pilotto
Journal:  N Engl J Med       Date:  1995-10-26       Impact factor: 91.245

View more
  17 in total

1.  Inhibitory potency of twice-a-day omeprazole on gastric acidity is enhanced by eradication of H. pylori in duodenal ulcer patients.

Authors:  A B R Thomson; M Keelan; R Lastiwka; S Appelman-Eszczuk; L Zuk; L Drozdowski; A Prentice; P Sinclair
Journal:  Dig Dis Sci       Date:  2003-10       Impact factor: 3.199

2.  A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory non-erosive reflux disease.

Authors:  Kyoichi Adachi; Kenji Furuta; Hiroto Miwa; Tadayuki Oshima; Masaharu Miki; Yoshinori Komazawa; Katsuhiko Iwakiri; Takahisa Furuta; Tomoyuki Koike; Tomohiko Shimatani; Yoshikazu Kinoshita
Journal:  Dig Dis Sci       Date:  2012-02-26       Impact factor: 3.199

3.  Validation of the blood quininium resin test for assessing gastric hypochlorhydria.

Authors:  Catherine De Martel; Sarah Ratanasopa; Douglas Passaro; Julie Parsonnet
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

4.  Helicobacter pylori infection in patients with erosive esophagitis is associated with rapid heartburn relief and lack of relapse after treatment with pantoprazole.

Authors:  José L Calleja; Manuel Suarez; Alberto Herreros De Tejada; Angel Navarro
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

5.  Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry.

Authors:  Tomohiko Shimatani; Masaki Inoue; Tomoko Kuroiwa; Jing Xu; Susumu Tazuma; Yoko Horikawa; Masuo Nakamura
Journal:  Dig Dis Sci       Date:  2005-07       Impact factor: 3.199

6.  Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes.

Authors:  Seiichi Hayato; Setsuo Hasegawa; Seiichiro Hojo; Hiroki Okawa; Hiroaki Abe; Nobuyuki Sugisaki; Masahiro Munesue; Yukio Horai; Akihiro Ohnishi
Journal:  Eur J Clin Pharmacol       Date:  2011-11-23       Impact factor: 2.953

7.  Comparison of PPIs and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia.

Authors:  Masahiro Sakaguchi; Miyuki Takao; Yasuo Ohyama; Hiroshi Oka; Hiroshi Yamashita; Takumi Fukuchi; Kiyoshi Ashida; Masahiro Murotani; Masuyo Murotani; Kazuo Majima; Hiroshi Morikawa; Takashi Hashimoto; Keisuke Kiyota; Hirohiko Esaki; Kanji Amemoto; Gouhei Isowa; Fumiyuki Takao
Journal:  World J Gastroenterol       Date:  2012-04-07       Impact factor: 5.742

8.  The effect of intragastric ammonia production on titratable gastric acid output in Helicobacter pylori-infected patients with chronic gastritis.

Authors:  Bogdan Cylwik; Jan W Dlugosz; Andrzej Kemona; Maciej Szmitkowski
Journal:  Dig Dis Sci       Date:  2005-11       Impact factor: 3.199

Review 9.  NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management.

Authors:  Francis K L Chan
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

10.  Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial.

Authors:  J C Y Wu; F K L Chan; J Y L Ching; W-K Leung; Y Hui; R Leong; S C S Chung; J J Y Sung
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.